HC Wainwright Reiterates “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $221.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 20.71% from the company’s current price. HC Wainwright also issued estimates for Krystal Biotech’s FY2026 earnings at $7.02 EPS.

Other analysts also recently issued reports about the company. Evercore ISI raised their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital lifted their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Finally, Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Trading Up 5.0 %

Shares of NASDAQ:KRYS opened at $183.09 on Tuesday. The business has a 50-day moving average price of $181.39 and a 200 day moving average price of $180.25. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 103.44 and a beta of 0.82. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period last year, the company earned ($0.67) EPS. As a group, equities research analysts predict that Krystal Biotech will post 2.88 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Huntington National Bank lifted its stake in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares during the last quarter. KBC Group NV lifted its stake in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares during the last quarter. Pier 88 Investment Partners LLC lifted its stake in Krystal Biotech by 5.1% during the third quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company’s stock worth $643,000 after purchasing an additional 170 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Krystal Biotech during the third quarter worth approximately $235,000. Finally, Prime Capital Investment Advisors LLC lifted its stake in Krystal Biotech by 93.1% during the third quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company’s stock worth $472,000 after purchasing an additional 1,249 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).